MedDay Pharmaceuticals SAS

https://www.medday-pharma.com

MedDay is a biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer) who has 25 years of experience in drug development and clinical research in the pharmaceutical industry. In April 2013, InnoBio, a biotechnology fund managed by BPIFrance, and Sofinnova Partners together invested a total of €8 million in MedDay. The Company’s most advanced pipeline candidate is MD1003 for the treatment of primary and secondary progressive multiple sclerosis. MD1003 is currently being investigated in 2 pivotal phase III studies in France, involving 250 patients. The first patient was included in October 2013 and the Company expects to announce the data from the MD1003 studies in 2015. *

	Start	2011-01-01 established
	Industry	MD1003 (high-dose D-biotin, MedDay)
	Industry 2	SPECMET metabolomics drug discovery platform
	Person	Sedel, Frédéric (MedDay 2011– CEO + Co-Founder)

	Region	Paris
	Country	France
	Street	47 Boulevard de l’Hôpital ICM-Brain and Spine Institute-IPEPs, Groupe Hospitalier Pitié Salpêrière
	City	75013 Paris
	Tel	+33-1-8417-7604
		Address record changed: 2020-12-02

Basic data	Employees	A: 1 to 10 (2014-11-24)

		* Document for »About Section«:

		Record changed: 2024-03-30

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for MedDay Pharmaceuticals SAS

[1] MedDay Pharmaceuticals SAS. (3/10/20). "Press Release: MedDay Reports Top-line Data from Phase III Trial »SPI2« for Treatment of Progressive Forms of Multiple Sclerosis". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]